Q-omics provides the consensus-scored LRRC63 profile across patient tissues and cancer cell-line models. LRRC63 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LRRC63 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, LRRC63 RNA expression shows 17,909 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where LRRC63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC63 survival associations across molecular data types. LRRC63 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC63 RNA expression–survival associations across cancer types. High LRRC63 expression shows unfavorable associations in BLCA, LGG, UCEC, ESCA, DLBC and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for LRRC63 RNA expression.
This table summarizes LRRC63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC63 shows lower tumor expression in KICH, LUSC, LUAD and KIRC and higher tumor expression in BRCA and LIHC. The KICH box plot shows higher LRRC63 RNA expression in normal versus tumor tissue (log2 FC = −0.434, t-test p < 0.001).
This table shows molecular features associated with LRRC63 in patient tissues and cancer cell lines. In patient samples, LRRC63 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
